Precocious puberty
Central precocious puberty in children. GnRH analogs (triptorelin) delay the pituitary LH/FSH axis — an approved paediatric indication.
Peptides on this topic
3 peptiden met onderzoek naar dit onderwerpHistrelin is a nonapeptide GnRH agonist delivered as a once-yearly implant. Approved for central precocious puberty in children (Supprelin LA) and advanced prostate cancer (Vantas).
- Humane RCTSuppresses sex hormones via a yearly implant — in precocious puberty and prostate cancer.
- Humane studieImplant form (once a year) instead of regular injections.
Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation.
- Humane RCTWith continuous exposure, LH and FSH are suppressed, with subsequent lowering of sex steroids.
- Humane RCTIn randomized endometriosis studies, leuprorelin was associated with greater reduction of pain parameters versus placebo.
Synthetic decapeptide GnRH agonist with increased affinity over native gonadotropin-releasing hormone. FDA- and EMA-approved since the 1980s for prostate cancer, endometriosis and precocious puberty.
- Humane RCTSuppression of testosterone into the castration range (<50 ng/dL) within 4 weeks in men with prostate cancer documented
- Humane RCTReduction of endometriosis pain and lesion size demonstrated versus placebo in randomised trials